Research and Your data

As a primary care provider and part of the National Health Service we do participate in medical research projects.  Please rest assured that your data is not shared with any research provider without your express consent.  All research projects are undertaken with NIHR Clinical Research Network or providers that are ISO2700 and ICH-GCP certified and also NHS IG compliant.  We also ensure that all research providers adhere fully with the DPA 1988 and GDPR legislation.

The following links provide you with more information.



In addition this page will list all research projects we are currently involved for your information.

Current Research projects


The I-WOTCH study is developing a support programme that aims to improve the everyday functioning for people living with chronic (long-term) pain and reduce their opioid (strong morphine-like painkillers) use.

The I-WOTCH study is a randomised controlled trial which is comparing two different treatments for people with long-term pain. The two treatments are:

GROUP 1 Usual GP care plus a opioid information booklet and relaxation CD

GROUP 2 A support programme in addition to the above.

Please see 'Information for the public' for more detailed information.

The purpose is to find out which treatment is best at helping people to live better with their pain and reduce their use of opioids. This trial will help us identify which treatment is more effective. It will measure the everyday functioning and opioid use of all the people in the trial at different time points. We hope that the results of this study will be used to help patients with chronic long-term pain in the future.


DECIDE is a 104 week multicentre trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between Forxiga (dapagliflozin) and Standard of Care (SOC).

Forxiga (dapagliflozin) is a drug and which in previous scientific studies has been shown to be safe and to improve diabetes management. This study is being carried out to confirm Forxiga’s effectiveness and tolerability in treating diabetes when used in everyday practice. To do this, Forxiga will be compared with the standard of care treatments. Medications that will be used in this study are all ones that are currently prescribed in the UK. The study will help doctors to decide whether Forxiga is a suitable long-term treatment for patients with type 2 diabetes who have not been able to manage on other drugs, when used in real life practice.

Approximately 880 patients will take part in this study in the United Kingdom. The study will last 2 years. The study will include information provided by participating patients through questionnaires, as well as information from routine health check-ups collected from electronic medical records.




HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users. It will be run by the University of Nottingham, with recruiting centres across the UK. This trial is funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme.

Aspirin use is widespread and increasing in elderly patients. The main hazard is gastrointestinal bleeding, which may be increasing because of increasing aspirin use. This trial is based on evidence that peptic ulcer bleeding in aspirin users occurs predominantly in H. pylori positive people.

Patients will be identified by their GPs, then asked to attend an appointment with a Research Nurse to consent to the trial and take a H. pylori breath test. Those with a positive result will be randomised to receive a one week course of either eradication treatment or placebo. No follow-up visits are required, but instead information will be extracted from the patients' electronic medical record using the MiQuest search tool.

The trial will continue until 87 adjudicated events (hospitalisation because of definite or probable peptic ulcer bleeding) have occurred, which would occur after a mean 2.5 patient years of follow-up, if trial assumptions are correct.